Sotio Announces First Patient Dosed In Part B Of Phase 1/1B Study With So-C101 In Combination With Pembrolizumab In Patients With Solid Tumors

Sotio, A Clinical Stage Immuno-Oncology Company Owned By Ppf Group, Today Announced That The First Patient Has Been Dosed In Part B Of The Ongoing Phase 1/1B Study Of Il-15 Superagonist, So-C101, For The Treatment Of Patients With Advanced/Metastatic Solid Tumors. Part B Will Examine So-C101 In Combination With Pd-1 Inhibitor Pembrolizumab. The Trial Is Conducted In Partnership With Cytune Pharma.Early Results From The Ongoing Part A Of The Phase 1/1B Trial Investigating So-C101 Monotherapy Dose Escalation To Date Have Shown Encouraging Biological Activity, Activating Nk Cells And Cd8 T Cells In Various Solid Tumors. Part B Now Allows For The Pembrolizumab Combination Phase Of This Dose-Escalation Study To Progress. &Ldquo;Given Its Mechanism Of Action As A Pure Il-15 Receptor Agonist, So-C101 Has Promising Potential For A Combination Approach With Checkpoint Inhibitors. We Are Pleased To Have Reached This Important Milestone And Look Forward To Investigating So-C101 In Combination With Pembrolizumab,&Rdquo; Said Radek ŠPÍŠEk, Ph.D., Chief Executive Officer Of Sotio.Dr. David Bechard, President And Chief Operations Officer Of Cytune Pharma, Added, &Ldquo;We Are Thrilled To Be Advancing Our Collaboration With Sotio And Begin Enrolling Patients In This Important Phase Of The Clinical Trial. There Remains A High Unmet Medical Need To Evaluate Novel Potent Immunotherapies For Patients With Cancer.&Rdquo;The Ongoing Multicenter, Open-Label Phase 1/1B Study, Sc103 (Nct04234113), Is Evaluating The Safety And Preliminary Efficacy Of So-C101 As Monotherapy (Part A) And In Combination With Pembrolizumab (Part B) In Patients With Selected Relapsed/Refractory Advanced/Metastatic Solid Tumors.Cytune Pharma Is Responsible For The Clinical Development Of So-C101, Sotio Is A Sponsor Of The Phase 1 Clinical Trial. Both Companies Are Owned By Ppf Group.About Sotiosotio Is Shaping The Future Of Cancer Immunotherapies By Translating Compelling Science Into Patient Benefit. Sotio&Rsquo;S Robust Clinical Pipeline Includes A Differentiated Superagonist Of The Attractive Immuno-Oncology Target Il-15, A Platform To Streamline Personalized Active Immune Cell Therapies And A New Generation Of Potent And Stable Antibody-Drug Conjugates (Adcs). Sotio Is A Member Of The Ppf Group. Sotio Is A Registered Trademark Of Sotio A.S. In Selected Countries.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!